Skip to content
Tenfell
Awarded contract
Published 10 May 2018

NHS Framework Agreement - North of England - Tranche B

NHS England · London

Key facts

Awarded
13 Feb 2018
Contract starts
01 Mar 2018
Contract ends
29 Feb 2020
Procedure
Open procedure
Buyer type
Central government

Awarded to 37 suppliers

SupplierValue
Takeda UK Limited—
Janssen-Cilag Ltd—
Merck Sharp & Dohme UK Ltd—
Pfizer Ltd—
Teva UK Ltd—
BAYER PUBLIC LIMITED COMPANY—
Napp Pharmaceuticals—
Sandoz Ltd—
Eli Lilly & Company Ltd—
Gedeon Richter UK Ltd—
Gilead Sciences Limited—
Ipsen—
Merck Serono Limited—
Novartis Pharmaceuticals UK Ltd—
Novo Nordisk—
Roche Products Ltd—
UCB Pharma Ltd—
Intrapharm Laboratories Ltd—
Ferring Pharmaceuticals Limited—
Mercury Pharmaceuticals Limited—
Bristol-Myers Squibb Pharmaceuticals Ltd—
ROVI Biotech Ltd—
Biogen Idec Ltd.—
Astellas Pharma Ltd—
Pharmasure—
Daiichi Sankyo UK Ltd—
Genzyme Therapeutics Ltd—
Aventis Pharma Limited t/a Sanofi—
LEOPHARMA LIMITED—
OEHRINGER INGELHEIM LIMITED—
Aventis Pharma Ltd Trading As Sanofi—
Bayer plc—
MSD—
Biogen—
LEO Pharma Ltd—
Boehringer Ingelheim—
Merck—

Description

A framework is awarded for the supply of proprietary pharmaceuticals to participating Authorities in the NHS Region: North of England. The period of the resulting framework is 01 March 2018 - 29 February 2020, with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Additional information: Attached is the model form framework agreement. All of the awarded frameworks were made on the basis of the model form framework agreement.

Redacted award schedules have been attached for each of the awarded suppliers.

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.